Paul MampillyPaul Mampilly

Back when Paul Mampilly was growing up in India, nobody talked about the stock market. Yet as a kid, Paul read voraciously about the Great Crash of 1929 and found it fascinating.

When he turned 18, he came to the United States by himself. Since then, he’s had close to 25 years of investment experience, and he’s been through every kind of job in finance.

He’s covered biotech and health care as an analyst and portfolio manager for major international banks such as Deutsche Bank, ING and Bankers Trust. He writes:

I’ve been part of a team managing a $23 billion mutual fund and a $6 billion hedge fund that Barron's named as one of the world's best hedge funds in 2008.

My clients have included European aristocracy, the Templeton Foundation, Swiss private banks, Fortune 500 companies like Sears and giant banks like the Royal Bank of Scotland.

He’s learned investing through experience, and he taught himself molecular biology simply by reading books. In fact, Paul has a personal library of over 1,000 books, and he never stops buying more. “On average, I read over 50 books a year and consume over 100 email news items every single day,” he says.

Welcome to Agora Financial’s FDA Trader!

Hello there, and welcome to Agora Financial’s FDA Trader! My name is Paul Mampilly. I’ll be your editor. Below, I share with you what I think to be the greatest wealth-building opportunity available to investors today. And I’ll share with you the approach I will take to every single recommendation you’ll read in about in our exciting new service. But before I do that, I’d like to share with you a little bit about myself...